Back to Search Start Over

Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols.

Authors :
Condorelli RA
Cannarella R
Crafa A
Barbagallo F
Gusmano C
Avola O
MongioƬ LM
Basile L
Calogero AE
La Vignera S
Source :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2022 Jun; Vol. 23 (9), pp. 1081-1090. Date of Electronic Publication: 2022 Apr 03.
Publication Year :
2022

Abstract

Introduction: Several antioxidants are available for the treatment of male infertility. Although the benefit of myo-inositol (MYO) and D-chiro-inositol (DCI) for female infertility is recognized, their role in male infertility is a matter of debate.<br />Areas Covered: The authors review the impact that treatment with MYO and/or DCI may have on conventional and bio-functional sperm parameters [mitochondrial membrane potential (MMP), sperm chromatin compactness, and sperm DNA fragmentation (SDF)], seminal oxidative stress (OS), and pregnancy, miscarriage, and live birth rates, and the possible mechanisms involved. Furthermore, the authors gather evidence on the effects of MYO and/or DCI on sperm function in vitro .<br />Expert Opinion: MYO can improve sperm count, motility, capacitation, acrosome reaction, and MMP. No data are currently available on the effects of DCI in vivo . Both MYO and DCI ameliorate sperm motility and MMP in vitro . Therefore, the use of inositols should be preferred in patients with idiopathic asthenozoospermia, especially in case of impaired sperm mitochondrial function. Due to their insulin-sensitizing action, a role for these molecules may be envisaged for the treatment of infertility caused by carbohydrate metabolism derangement.

Details

Language :
English
ISSN :
1744-7666
Volume :
23
Issue :
9
Database :
MEDLINE
Journal :
Expert opinion on pharmacotherapy
Publication Type :
Academic Journal
Accession number :
35348407
Full Text :
https://doi.org/10.1080/14656566.2022.2060076